Fig. 1 · Structure

Documents & Downloads

GANT 58

Cat. No. A11442 CAS 64048-12-0

GLI antagonist

GANT 58 is a potent Gli antagonist that inhibits GLI1-induced transcription with IC50 of 5 μM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
Shh Light II IC50 5 μM Inhibition of SHH in mouse Shh Light2 cells by GLI-responsive firefly luciferase reporter gene assay [PMID: 19309080]

GANT 58 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of GANT 58 from 3 published references. In vitro models include MDA-MB-231 cells; TDSCs isolated from SD rats. In vivo models include female C57BL/6J mice, aged 6–8 weeks; BALB/c nude mice.

GANT 58 In Vitro Studies

In MDA-MB-231 cells exposed for 72 h, GANT 58 could start to reduce proliferation at the highest dose of 100 μM. In TDSCs isolated from SD rats under osteogenic induction, GANT 58 at 25 mM reduced ROS levels relative to vehicle after 48 h, as measured by flow cytometry. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Could Start to Reduce the Cell Proliferation of MDA-MB-231 Cells

Cell-based study · MDA-MB-231 cells [1]

MDA-MB-231 cells were exposed to treatment at 100 μM for 72 h. Treatment could start to reduce cell proliferation at this highest dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result could start to reduce the cell proliferation of MDA-MB-231 cells at the highest dose of 100 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
72 h
Method
exposing the cells
Vehicle
Dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: GANT 58

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Reduced Cell Viability by Gli Inhibitors (S12, S13); 4. Materials and Methods > 4.3. Cell Viability Assay (S62); Figure 3 legend (S89, S92)

cell viability: cell viability; comparator: Dimethyl sulfoxide (DMSO) (0 μM) — 2. Results > 2.3. Reduced Cell Viability by Gli Inhibitors (S13); Figure 3 legend (S89)

Reduced Reactive Oxygen Species Under Osteogenic Induction

Cell-based study · TDSCs isolated from SD rats [2]

TDSCs isolated from SD rats received GANT 58 at 25 mM under osteogenic induction for 48 h. Flow cytometry showed reduced reactive oxygen species levels compared with the vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
reactive oxygen species (ROS) levels by flow cytometryROS levels by flow cytometry 0.84 ± 0.04-fold above vehicle group[2]

Literature-Reported Treatment Conditions

Treatment concentration
25 mM
Exposure duration
48 h
Method
under osteogenic induction
Vehicle
DMSO
Co-treatment
Other interventions in this design: dexamethasone 10−8 M; vitamin C 50 μg/mL; β-glycerol phosphate 10 mM. Compound effect isolated by the comparison: vehicle group.
Methods and source locations

Compound reported in the paper: GANT 58

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. GANT58 and SAG Administration (S11, S12); 2. Materials and Methods > 2.6. Cells Culture (S33); 2. Materials and Methods > 2.9. Measurement of Intracellular ROS Levels (S45); 3. Results > 3.4. Regulation of Hh Signalling Affects Osteogenesis and Chondrogenesis of TDSCs In Vitro (S77); 3. Results > 3.5. Hh Signalling Regulates Antioxidant Pathway in Osteogenic Differentiation of TDSCs (S88); Figure 6 legend (S140)

reactive oxygen species (ROS) levels by flow cytometry: reactive oxygen species (ROS) levels by flow cytometry; comparator: An equal amount of the vehicle — 3. Results > 3.5. Hh Signalling Regulates Antioxidant Pathway in Osteogenic Differentiation of TDSCs (S88); Figure 6 legend (S140)

GANT 58 In Vivo Studies

In female mice after Achilles tenotomy, intraperitoneal GANT 58 significantly reduced ectopic bone areas in injured tendon sections compared with the DMSO vehicle group. In BALB/c nude mice bearing HuCCT1 xenografts, GANT 58 treatment significantly reduced subcutaneous tumor size and weight compared with the DMSO control. [2,3]

Reduced Ectopic Bone Areas After Achilles Tenotomy

Animal study · Female C57BL/6J mice, aged 6–8 weeks [2]

Female mice received GANT 58 intraperitoneally after Achilles tenotomy, with DMSO as the vehicle control. Treatment significantly reduced ectopic bone areas in injured tendon sections.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
areas of ectopic bones in injured tendon sections at 10 weeksectopic bone area 0.24 ± 0.09-fold above vehicle group[2]

Conditions shared by the study groups

Route
injected intraperitoneally (i.p.)
Treatment course
every day (50 mg/kg, 100 μL/mouse) from day 1 to week 6 after Achilles tenotomy
Vehicle
dimethyl sulfoxide (DMSO)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GANT 58 50 mg/kg, 100 μL/mouseAn equal volume of DMSOGANT58 significantly reduced the areas of ectopic bones in injured tendon sections at 10 weeks (0.24 ± 0.09-fold above vehicle group; p < 0.01)[2]
GANT 58 50 mg/kg, 100 μL/mouse
Model: Female C57BL/6J mice, aged 6–8 weeks
Methods and source locations

Compound reported in the paper: GANT 58

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animal Model and Grouping (S1); 2. Materials and Methods > 2.2. GANT58 and SAG Administration (S8, S10); 2. Materials and Methods > 2.4. Histologic, Histochemical and Immunohistochemical (IHC) Analyses (S16); 3. Results > 3.2. Inhibition of Hh Signalling Restricts Posttraumatic Tendon Endochondral Ossification (S56)

areas of ectopic bones in injured tendon sections at 10 weeks: areas of ectopic bones in injured tendon sections at 10 weeks; comparator: An equal volume of DMSO — 3. Results > 3.2. Inhibition of Hh Signalling Restricts Posttraumatic Tendon Endochondral Ossification (S56)

GANT 58 50 mg/kg, 100 μL/mouse · 2. Materials and Methods > 2.2. GANT58 and SAG Administration (S8); 3. Results > 3.2. Inhibition of Hh Signalling Restricts Posttraumatic Tendon Endochondral Ossification (S56)

Reduced Subcutaneous Xenograft Tumor Size and Weight

Animal study · BALB/c nude mice [3]

BALB/c nude mice bearing HuCCT1 xenografts received GANT 58 at 25 mg/kg or DMSO. Tumor size and weight were significantly lower with treatment than in the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
volumes of the HuCCT1 xenograftsReported result the size and weight of subcutaneous xenograft tumors treated with GANT58 were significantly lower than those in the control group[3]

Conditions shared by the study groups

Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GANT 58 25 mg/kgDMSOthe size and weight of subcutaneous xenograft tumors treated with GANT58 were significantly lower than those in the control group[3]
GANT 58 25 mg/kg
Model: BALB/c nude mice
Reported limits: Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: GANT 58

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > EHF promotes CCA proliferation and development by upregulating GLI1 expression in nude mice (S54); MATERIALS AND METHODS > Animal studies (S101, S102); FIGURE 5 legend (S242)

volumes of the HuCCT1 xenografts: volumes of the HuCCT1 xenografts; comparator: DMSO — RESULTS > EHF promotes CCA proliferation and development by upregulating GLI1 expression in nude mice (S54); FIGURE 5 legend (S242)

GANT 58 25 mg/kg · RESULTS > EHF promotes CCA proliferation and development by upregulating GLI1 expression in nude mice (S54); FIGURE 5 legend (S242)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 64048-12-0
Applications GLI antagonist
Formula C24H16N4S
Molecular Weight 392.48
SMILES
C1=CN=CC=C1C2=C(SC(=C2C3=CC=NC=C3)C4=CC=NC=C4)C5=CC=NC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GANT 58 Research References

  1. [1] Jeng KS, Jeng CJ, Sheen IS, et al. Glioma-Associated Oncogene Homolog Inhibitors Have the Potential of Suppressing Cancer Stem Cells of Breast Cancer. Int J Mol Sci (2018). PMID: 29734730 DOI: 10.3390/ijms19051375 Source material
  2. [2] Li G, Deng Y, Li K, et al. Hedgehog Signalling Contributes to Trauma-Induced Tendon Heterotopic Ossification and Regulates Osteogenesis through Antioxidant Pathway in Tendon-Derived Stem Cells. Antioxidants (Basel) (2022). PMID: 36421451 DOI: 10.3390/antiox11112265 Source material
  3. [3] Luo Y, Li Z, Zhu H, et al. Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2. MedComm (2020) (2024). PMID: 38741887 DOI: 10.1002/mco2.535 Source material

Added to your cart

View Cart Checkout
Loading...